Humacyte, Inc. has announced that the FDA has granted full approval for SYMVESS, a novel bioengineered human tissue designed for use as a vascular conduit in patients with extremity arterial ...

Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to ...

Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit ...

(Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) ...

Fox. “SYMVESS shows promise to reduce amputation rates since an alternative conduit for war injuries is often needed but up until now has not been a good option.” “The FDA approval of ...